User:Mr. Ibrahem/Sodium phenylbutyrate/ursodoxicoltaurine

Sodium phenylbutyrate/ursodoxicoltaurine, also known as sodium phenylbutyrate/taurursodiol and sold under the brand name Albrioza among others, was a combination medication used to treat amyotrophic lateral sclerosis (ALS). It was subsequently shown to not be effective in 2024. It is given by mouth.

Common side effects include diarrhea, abdominal pain, nausea, and upper respiratory tract infection. It is high in sodium and care should be taken in those who are sensitive. Use in pregnancy may harm the baby. It contains sodium phenylbutyrate and ursodoxicoltaurine (taurursodiol). It was believed to work by altering pathways in mitochondria and endoplasmic reticulum that result in cell death.

The combination was approved for medical use in Canada and the United States in 2022. The manufacturer has applied for approve in Europe as of 2022. In Canada it costs about 220,000 CAD per person per year. In the United States it costs about 158,000 USD per year as of 2022. It was withdrawn from the market in 2024.